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Introduction: It is now well-recognised that patients with autoimmune rheumatic disease (AIRD) have a predisposition
to cardiovascular disease that results in increased morbidity and mortality. Following myocardial infarction (MI), patients
with rheumatoid arthritis have been shown to have an increased case fatality rate; however, this has not been
demonstrated in other forms of AIRD. The aim of this study was to compare case fatality rates following a first MI in
patients with AIRD versus the general population. The secondary aim was to compare revascularisation treatment
following MI in patients with AIRD versus the general population.
Methods: A retrospective cohort study using two population-based linked databases was undertaken. Cases of first
MI from July 2001 to June 2007 were identified based on International Statistical Classification of Diseases and Related
Health Problems, Tenth Revision, Australian Modification, codes. Thirty-day and one-year mortality rates were calculated
(all-cause and cardiovascular causes of death). Logistic regression models were fitted to calculate the odds of mortality
by AIRD status with adjustment for relevant characteristics.
Results: There were 79,390 individuals with a first MI, of whom 1,409 (1.8%) had AIRD. After adjusting for relevant
covariates, the odds ratio (OR) for 30-day cardiovascular mortality in patients with AIRD was 1.44 (95% confidence interval
(CI): 1.25 to 1.66), and the OR for 12-month cardiovascular mortality was 1.71 (95% CI: 1.51 to 1.94). The 90-day adjusted
odds of percutaneous transluminal coronary angioplasty and coronary artery bypass graft were significantly lower in the
AIRD group compared with controls (OR: 0.81, 95% CI: 0.70 to 0.94, and OR: 0.52, 95% CI: 0.39 to 0.69, respectively).
Conclusions: We identified a higher risk-adjusted mortality rate for the majority of patients with AIRD at 30 days and
12 months after first MI. We also identified lower post-MI revascularisation rates in the AIRD group, suggesting there may
be current gaps in cardiovascular treatment for patients with AIRD.Introduction
Diseases such as rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), systemic sclerosis (SSc), spondyloar-
thritis (SpA) and systemic vasculitis have differing clinical
presentations and immunopathogenic mechanisms, but
they share the common feature of chronic systemic inflam-
mation. These diseases, collectively referred to herein as* Correspondence: svd@unimelb.edu.au
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article, unless otherwise stated.autoimmune rheumatic disease (AIRD), also come with a
predisposition to cardiovascular disease (CVD) [1]. Inflam-
mation has been shown to be a critical aspect of the athero-
sclerotic process, influencing the development of
endothelial dysfunction, plaque rupture and thrombosis [2].
Systemic inflammation in AIRD may drive the progression
of underlying atherosclerotic disease, contributing to the in-
creased CVD morbidity and mortality experienced by pa-
tients with AIRD [3-5].
A 2008 meta-analysis utilising data from 24 studies
and 111,758 patients with RA (up to July 2005) reportedCentral. This is an Open Access article distributed under the terms of the
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causes of 1.5 (95% CI: 1.39 to 1.61) [6]. This increased CV
mortality can be partially explained by an increased inci-
dence of myocardial infarction (MI) and other CVD
[7-10]. However, we have demonstrated that patients with
RA also have an increased case fatality rate following MI
(adjusted odds ratio (OR) of 30-day mortality: 1.9 (95% CI:
1.3 to 2.7)) [11], a finding that has been replicated by
others [9,12]. This increased case fatality rate may be
partly explained by lower rates of post-MI treatment with
acute revascularisation and/or cardioprotective drugs [13].
However, other possibilities include delays in the diagnosis
of MI [14], the effect of concurrent medications (such as
nonsteroidal anti-inflammatory drugs) [15,16], reduced
physical activity and/or detrimental effects of systemic in-
flammation [17]. Patients with other forms of AIRD also
have these potential risk factors and may also experience
increased post-MI case fatality; however, this has not pre-
viously been investigated.
The primary aim of this study was to examine 30-day
and 1-year mortality following a first acute MI in patients
with AIRD versus the general population. The secondary
aim was to compare revascularisation treatment (percutan-
eous transluminal coronary angioplasty (PTCA) and coron-
ary artery bypass grafts (CABG)) following MI in patients
with AIRD versus the general population.
Methods
Data sources
Two Australian population-based datasets, the Victorian
Linked Dataset (VLD) and the Western Australian Data
Linkage System (WADLS), which cover approximately
35% of the Australian population, were utilised [18]. Both
datasets include hospital and emergency presentation data
from all private and public hospitals across the state, along
with linked national death data [19,20]. An evaluation of
the WADLS linkage has shown that the extensive prob-
abilistic matching procedures based on patient names and
other partial identifiers are 99.89% accurate [20].
These datasets contain deidentified demographic and
clinical information on each episode of patient care, with
clinical information coded in the format of the Inter-
national Statistical Classification of Diseases and Related
Health Problems, Tenth Revision, Australian Modification
(ICD-10-AM), beginning 1 July 1998 and the ICD Ninth
Revision, Canadian Modification (ICD-9-CM), prior to 1
July 1998 [21]. The Victorian Department of Health main-
tains data quality with an annual independent audit cycle
that samples nearly 1% of public hospital discharges. In
the most recent audit, the sensitivity and positive predict-
ive value of the hospital discharge coding for MI were 86%
(95% CI: 80% to 93%) and 96% (95% CI: 92% to 100%), re-
spectively, and for RA they were 91% (95% CI: 74% to
100%) and 77% (95% CI: 54% to 100%) [22]. The VLDprovides place of residence information at the Australian
census-derived Statistical Local Area (SLA) level, whereas
the WADLS provides place of residence information at a
postcode level.
Definition of index myocardial infarction and
autoimmune rheumatic disease
All cases of MI from 1 July 2001 to 30 June 2007 were iden-
tified based on the ICD-10-AM classifications (Additional
file 1). An individual was considered to have experienced a
first acute MI if she had a diagnosis of MI within this time
period and no diagnosis of MI in the previous 5 years; that
is, each dataset has records back to 1st July 1996 to provide
a five-year ‘look-back’ period. A 5-year look-back period
was chosen as this has been shown to exclude the vast ma-
jority of individuals who have experienced a prior MI, and
it is likely that less than 5% of the remaining population
have experienced an MI more than 5 years previously [23].
For the purposes of this study, AIRD included the follow-
ing diagnoses: RA, SLE, psoriatic arthritis (PsA), ankylosing
spondylitis (AS), enteropathic arthritis (EA), undifferentiated
SpA, SSc, systemic necrotising vasculitis, Sjögren’s syn-
drome, polymyalgia rheumatica (PMR), mixed connective
tissue disease (MCTD), dermatomyositis (DM) and poly-
myositis (PM). Each of these conditions was considered to
be present when the relevant ICD-9-CM or ICD-10-AM
diagnostic codes (see Additional file 1) were recorded dur-
ing the index MI admission or during any admission in the
3 years prior to the index MI. We also aggregated PsA, AS,
EA and undifferentiated SpA into a SpA group. We chose a
3-year look-back period for identifying AIRD after compar-
ing different look-back periods in a sensitivity analysis. We
found that the 3-year look-back provided optimal ascertain-
ment of AIRD while still providing sufficient years of data
to address our aims [24]. Patients who had more than one
AIRD condition coded during the look-back period were
considered to have AIRD and were therefore counted only
once in the primary analysis.
Outcomes
Mortality
Thirty-day and one-year mortality rates were calculated
from the admission date of the index MI episode to the
date indicated in the death registry data. Deaths occurring
outside the hospital based on death reports to the death
registry were also considered. For the VLD, cause of death
was provided in a text format. To identify CV deaths, we
used a text string-searching algorithm for the causes of
death, allowing for permutations of the following words:
myocardial infarction, angina pectoris, ischemic heart dis-
ease, congestive heart failure, cardiomyopathy, arrhyth-
mias, pulmonary oedema, stroke, thromboembolism, and
cardiac arrest. For the WADLS dataset, cause of death was
provided in ICD-10-AM code format (Additional file 1).
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Procedure codes for PTCA and CABG were identified
within the index MI episode or in any subsequent ad-
mission episode up to 90 days after the index MI to
compare revascularisation rates for AIRD and non-AIRD
patients (Additional file 1). As these procedures were
not time- or date-stamped in the dataset, we were un-
able to identify the exact timing in relation to the MI
event.
Other covariates
Covariates in the adjusted models included age, sex, socio-
economic status (SES), proximity to goods and services and
comorbidities of interest (based on the Charlson comorbid-
ity algorithm [25,26]) (Additional file 1). We also included
smoking, hypertension and hypercholesterolaemia in our
analyses.
SES was indicated by the Index of Relative Socio-
economic Disadvantage (IRSD), a measure included in
the Socio-Economic Indexes of Areas (SEIFA) developed
by the Australian Bureau of Statistics [27,28]. The IRSD
is derived from census survey data related to disadvan-
tage, such as low income, low educational attainment,
unemployment and dwellings without motor vehicles.
This index is thought to be most closely aligned with
low SES and has been shown to be a predictor of poorer
health outcomes and greater hospital utilisation [29]. A
dichotomous variable reflecting residential areas in the
lowest quartile (those with the greatest disadvantage)
compared with those in the top three quartiles was gen-
erated from the IRSD.
Access to goods and services, including health care
services, was determined by using the Accessibility/Re-
moteness Index of Australia (ARIA) measure [30]. This
is an area-based measure based on each patient’s resi-
dential location. A dichotomized variable was generated
to reflect those individuals whose place of residence was
classified as ‘highly accessible’, indicating unrestricted ac-
cess to goods and services, compared with those with re-
stricted access.
Statistical analysis
After initial descriptive statistics and exploratory bivari-
ate analysis, logistic regression models were fitted with
AIRD status as the key exposure variable and 30-day
and 1-year mortality rates (all-cause and CV) as the out-
come. Covariate adjustments included age, sex, IRSD,
ARIA and relevant comorbidities (see Figure 1 for
complete list). χ2 analyses were used to compare inter-
vention rates in patients with versus without AIRD. Lo-
gistic regression analyses were used to examine the odds
of receiving interventions by AIRD status after adjust-
ment for age, sex, remoteness index, SES and comorbidi-
ties. Given the potential gain in efficiency of matchingcases to controls, a sensitivity analysis was undertaken
to explore this strategy. Non-AIRD controls were
matched to AIRD cases on age and sex in a 5:1 ratio. All
analyses were conducted using STATA statistical analysis
software, version 12.1 (StataCorp, College Station, TX,
USA). Ethical approval for this study was obtained from
the Melbourne Health Human Research Ethics Commit-
tee. Individual patient consent was not required, as was
determined by the ethics committee.
Results
There were 79,390 individuals who experienced a first
MI during the study period, of whom 1,409 (1.8%) had
AIRD. The demographic and clinical characteristics of
these patients are shown in Table 1 for the AIRD group
overall and for the disease subgroups in Additional file
2. The patients with AIRD were older than those in the
non-AIRD group (median (interquartile range) age:
77 years (68 to 83) versus 74 years (61 to 82)), more
likely to be female (63.5% versus 39.1%) and less likely to
be treated in public hospitals (63.7% versus 66.8%). Pa-
tients with AIRD were also more likely to have renal dis-
ease (20.2% versus 12.4%), pulmonary disease (11.4%
versus 7.6%) and cerebrovascular accident (7.3% versus
5.4%). Patients with AIRD were less likely to have hyper-
tension (41.1% versus 44.5%), a current history of smok-
ing (11.9% versus 20.3%), hypercholesterolaemia (10.2%
versus 16.4%) or cancer (4.7% versus 6.1%). The num-
bers of patients by AIRD subtype are reported in
Table 2.
Mortality outcomes
The number of deaths in the AIRD and non-AIRD pa-
tients at 30 days and 12 months after the index MI, as
well as the crude and adjusted ORs for mortality, are
shown in Table 3. The 30-day all-cause mortality for
AIRD and non-AIRD patients was 21.4% and 13.4%, re-
spectively (P < 0.001). After adjusting for age, sex, SES,
ARIA and relevant comorbidities, the OR for 30-day all-
cause mortality in the AIRD group was 1.44 (95% CI:
1.26 to 1.65). The 30-day CV mortality for AIRD and
non-AIRD patients was 18.9% and 11.7%, respectively
(P < 0.001), with a corresponding adjusted OR of 1.44
(95% CI: 1.25 to 1.66). At 12 months, the patients with
AIRD had an all-cause mortality rate of 38.6%, and that
of non-AIRD patients was 22.8% (P < 0.001), with an ad-
justed OR of 1.82 (95% CI: 1.61 to 2.05). The 12-month
CV mortality rates were 32.9% versus 19.4% in AIRD
and non-AIRD patients, respectively (P < 0.001), with an
adjusted OR of 1.71 (95% CI: 1.51 to 1.94). Figure 1
shows the adjusted ORs for the AIRD group overall,
along with adjusted ORs for the disease subgroups that
comprise the AIRD population. The adjusted ORs for
the disease subgroups are also presented in Table 4. The
Figure 1 Mortality risk for patients who experienced a first myocardial infarction between 1 July 2001 and 30 June 2007. *Spondyloarthritis
group includes ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis and undifferentiated spondyloarthritis. Reference group is patients
without autoimmune rheumatic disease (AIRD) or AIRD subgroup. For each AIRD subgroup, patients were excluded from the reference group
if they had any other AIRD type. Adjusted for age, sex, Socio-Economic Indexes for Areas, Index of Relative Socio-economic Disadvantage,
Accessibility/Remoteness Index of Australia high accessibility, individual Charlson comorbidities, smoking, hypertension and hypercholesterolaemia.
^95% CI, 95% confidence interval.
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matched data were similar and therefore are not re-
ported separately. They are available in Additional file 3.
Interventions
Rates of PTCA within the index admission were signifi-
cantly lower in the AIRD patient group than in the non-
AIRD patient group (AIRD 13.5% versus non-AIRD
25.9%, P < 0.001, crude OR: 0.53 (95% CI: 0.46 to 0.62))
(Table 5). This difference persisted after adjustment for
age, sex, ARIA, SEIFA and comorbidities (adjusted OR:
0.80 (95% CI: 0.68 to 0.94)). The intervention rates of
CABG within the index admission were also significantly
less in the AIRD patient group (2.5% versus 5.9%, P <
0.001, crude OR: 0.41 (95% CI: 0.29 to 0.57)), which per-
sisted after adjustment (adjusted OR: 0.50 (95% CI: 0.35
to 0.70)). In those who did not undergo intervention
during their index admission, intervention rates werehigher in the non-AIRD patient group than in the AIRD
patient group at 30 days and between 30 and 90 days, al-
though this was not significant for CABG at 30 days.
Following adjustment, there were no differences in inter-
vention rate at either 30 or 90 days.
Discussion
To our knowledge, this is the largest study of case fatal-
ity rates following MI in patients with AIRD. Patients
with AIRD experiencing a first MI had adjusted odds of
death that were 1.5 times greater than that for patients
without AIRD at 30 days (OR: 1.44, 95% CI: 1.26 to
1.65) and nearly two times that of patients without
AIRD at 12 months (OR: 1.82, 95% CI: 1.61 to 2.05).
Post-MI mortality was also significantly increased in
most subgroups, including RA, SLE, PsA and AS (at
30 days and 12 months) and SSc, vasculitis, PMR and
MCTD at 12 months. Sjögren’s syndrome was the only
Table 1 Patient demographic and clinical factorsa
AIRD Non-AIRD
Patients, n (%) 1,409 (1.8) 77,981 (98.2)
Age, median (IQR) 77 (68 to 83) 74 (61 to 82)
Female, n (%) 894 (63.5) 30,489 (39.1)
Indigenous,b n (%) 6 (2.0) 556 (3.7)
Married/de facto,b n (%) 137 (46.3) 9,007 (59.5)
High accessibility to services,c,d n (%) 1,232 (87.8) 67,550 (87.1)
Lowest quartile of SEIFA-IRSD, n (%) 190 (13.5) 11,102 (14.3)
Elective admission,e n (%) 213 (19.1) 10,923 (17.4)
Public hospital admission,e n (%) 709 (63.7) 41,965 (66.8)
Comorbidities at index admission, n (%)
Hypertension 579 (41.1) 34,687 (44.5)
Arrhythmia 437 (31.0) 22,202 (28.5)
Congestive heart failure 511 (36.3) 20,955 (26.9)
Smoker 168 (11.9) 15,816 (20.3)
Hypercholesterolaemia 143 (10.2) 12,750 (16.4)
Diabetes 300 (21.3) 16,183 (20.7)
Renal disease 284 (20.2) 9,649 (12.4)
Pulmonary disease 161 (11.4) 5,927 (7.6)
Cerebrovascular accident 103 (7.3) 4,227 (5.4)
Cancer 67 (4.7) 4,781 (6.1)
Obesity 47 (3.3) 3119 (4.0)
Paraplegia 51 (3.6) 2,262 (2.9)
Peripheral vascular disease 40 (2.8) 1,754 (2.3)
Dementia 28 (2.0) 1,326 (1.7)
Peptic ulcer disease 34 (2.4) 871 (1.1)
Liver disease 16 (1.2) 443 (0.6)
HIV 1 (<0.1) 30 (<0.1)
aAIRD, Autoimmune rheumatic disease; IQR, Interquartile range; IRSD, Index of
Relative Socio-economic Disadvantage; SEIFA, Socio-Economic Indexes of Areas.
bAvailable for Western Australia data only (n = 15,426). cBased on Accessibility/
Remoteness Index of Australia (ARIA) code 1, Major Cities, Highly Accessible.
dMissing data for ARIA in Victoria data (n = 444). eAvailable for Victoria data
only (n = 63,964).
Table 2 Number of autoimmune rheumatic disease
conditions by subtype
Condition Frequency, n %
Rheumatoid arthritis 736 52.2%
Polymyalgia rheumatica 255 18.1%
Systemic necrotising vasculitis 177 12.6%
Systemic lupus erythematosus 100 7.1%
Systemic sclerosis 67 4.8%
Ankylosing spondylitis 59 4.2%
Psoriatic arthropathies 38 2.7%
Spondyloarthritis 95 6.7%
Dermatomyositis/polymyositis 25 1.8%
Mixed connective tissue disease 23 1.6%
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tality after MI. This may be due to the small number of
patients (n = 22), as there is some evidence to suggest
cardiac involvement in these patients [31]. Although
dermatomyositis/polymyositis showed a positive associ-
ation with mortality after MI at 12 months, the associ-
ation was not significant. This also may be related to the
small number of patients in this group (n = 25).
There have been relatively few studies of post-MI case
fatality rates in patients with AIRD. Three studies in RA
populations have all demonstrated increased case fatality
rates following MI [9,11,12], whereas the results of two
studies of in-hospital mortality after MI in lupus patients
were inconsistent. In a comparison of outcomes after
acute MI in 519 SLE patients and 214,771 controls in aCalifornia hospitalisation database, in-hospital mortality
was not found to differ between the groups [32]. In con-
trast, a similar analysis using the 1993–2002 US Nation-
wide Inpatient Sample reported a hazard ratio (HR) of
1.65 (95% CI: 1.33 to 2.04) for in-hospital mortality in
SLE [33].
We also identified disparities in intervention rates be-
tween AIRD and non-AIRD patients within the index
admission. We recently reported similar findings in a
study of 90 patients with RA drawn from three Austra-
lian hospitals. In that study, we identified lower rates of
acute reperfusion in the RA group [13]. Similarly, in a
retrospective cohort study in the United States, re-
searchers reported lower rates of CABG (HR: 0.35, 95%
CI: 0.16 to 0.78) in a comparison of 1,206 age- and sex-
matched patients with RA and controls [14]. In contrast
to these findings, McCoy et al. reviewed medical records
from 1979 to 2009 in the United States, including 77 pa-
tients with RA, and identified no differences in interven-
tion rates, including thrombolytic therapy, PTCA and
CABG [34]. Francis et al. conducted a cross-sectional
analysis of 1,112,676 patients with MI in the United
States and found that patients with RA (n = 13,029) were
38% (95% CI: 10% to 71%) more likely to receive
thrombolysis and 27% (95% CI: 17% to 39%) more likely
to receive PTCA [35]. As patients with RA comprised
the majority of the cohort in our study (52%) and shared
similar demographic characteristics with the aforemen-
tioned studies, the differences in treatment patterns may
be related to practice variation in different geographical
areas. We did not identify any studies in which treat-
ment patterns in other (non-RA) AIRD populations were
examined.
The patients with AIRD in this study tended to be
older, were more likely to be female and/or unmarried
Table 3 Outcomes in patients with or without autoimmune rheumatic disease who experienced a first myocardial
infarction between 1 July 2001 and 30 June 2007a
Variable Non-AIRD (n = 77,981) AIRD (n = 1,409) Crude OR (95% CI) Adjusted ORb (95% CI)
30-day mortality, all cause 10,452 (13.4) 301 (21.4) 1.76 (1.54 to 2.00) 1.44 (1.26 to 1.65)
30-day mortality, cardiovascular 9,105 (11.7) 266 (18.9) 1.76 (1.54 to 2.02) 1.44 (1.25 to 1.66)
12-month mortality, all cause 17,766 (22.8) 544 (38.6) 2.13 (1.91 to 2.38) 1.82 (1.61 to 2.05)
12-month mortality, cardiovascular 15,095 (19.4) 464 (32.9) 2.05 (1.83 to 2.29) 1.71 (1.51 to 1.94)
aAIRD, Autoimmune rheumatic disease; OR, Odds ratio. bAdjusted for age, sex, Accessibility/Remoteness Index of Australia, Socio-Economic Indexes for Areas
and comorbidities.
Van Doornum et al. Arthritis Research & Therapy  (2015) 17:38 Page 6 of 9and had significantly higher rates of certain comorbidi-
ties, including renal disease, pulmonary disease, peptic
ulcer disease, cerebrovascular accident and liver disease
than non-AIRD patients. As some of these are known
risk factors for mortality and morbidity following coron-
ary intervention [36], clinicians may have been more re-
luctant to recommend invasive procedures for this
patient group. As we did not have detailed clinical data
on cardiac risk factors or clinician decision making, we
are not able to determine whether these factors influenced
intervention rates. Interestingly, patients with AIRD had
significantly lower rates of certain CV risk factors compared
with non-AIRD patients, including smoking, hypertension
and dyslipidaemia. This finding is consistent with previous
studies that have identified a clinical presentation of CVD
in patients with RA that is different from traditional CVD
presentation patterns, which may delay disease recognition
[11,14] and/or treatment [13].
Current guidelines recommend CV screening for pa-
tients with RA and consideration of monitoring patients
with AS and PsA [37]. Given the relationship between in-
flammatory processes and CVD, examining biomarkers of
inflammation and the presence of AIRD conditions may
be warranted as part of existing CVD risk predictionTable 4 Adjusted odds ratios for the autoimmune rheumatic
Condition Count 30-day mortality (adjuste
All causes C
Autoimmune rheumatic diseases 1,409 1.44 (1.26 to 1.65) 1
Rheumatoid arthritis 666 1.50 (1.24 to 1.81) 1
Systemic lupus erythematosus 93 2.81 (1.71 to 4.62) 2
Psoriatic arthropathies 25 2.61 (1.14 to 5.97) 3
Ankylosing spondylitis 38 2.14 (1.13 to 4.08) 2
Spondyloarthritisc 63 2.19 (1.30 to 3.67) 2
Systemic sclerosis 61 1.78 (0.95 to 3.33) 1
Systemic necrotising vasculitides 174 1.37 (0.95 to 1.98) 1
Sjögren’s syndrome 17 1.27 (0.42 to 3.86) 1
Polymyalgia rheumatica 239 0.96 (0.70 to 1.32) 1
Mixed connective tissue disease 19 0.78 (0.22 to 2.76) 0
Dermatomyositis/polymyositis 25 0.25 (0.03 to 1.95) 0
aStatistically significant results in bold. bAdjusted for age, sex, Accessibility/Remoten
cSpondyloarthritis group includes ankylosing spondylitis, psoriatic arthritis, enteropamodels. Identifying inflammatory markers has been shown
to be effective for detecting non-AIRD patients at high
risk of CV events. The findings of the JUPITER trial, in
which researchers examined the use of rosuvastatin as pri-
mary prevention therapy to reduce CV events in people
with elevated high-sensitivity C-reactive protein, support
the use of inflammatory biomarkers in assessing CV risk
[38]. A further study is underway to examine whether
inhibiting inflammation with methotrexate is effective for
reducing adverse CV outcomes [39]. Further research
should consider whether anti-inflammatory treatments in
patients with AIRD will contribute to reductions in CV
risk and mortality.
A major strength of our study is that we utilised two
population-based datasets with coverage of 35% of
Australia’s population, including hospital admissions,
emergency department presentations and deaths outside
the hospital. However, we must also acknowledge several
limitations. We utilized administrative datasets that are not
designed primarily for research purposes. Clinical informa-
tion in these types of data has been shown to have inaccur-
acies [40], and our estimates of CV risk factors may be
inaccurate. This risk of error is unlikely to be differentially
distributed between the groups, and therefore the risk ofdisease group overall and disease subgroupsa
d odds ratiob) 12-month mortality (adjusted odds ratiob)
ardiovascular All causes Cardiovascular
.44 (1.25 to 1.66) 1.82 (1.61 to 2.05) 1.71 (1.51 to 1.94)
.51 (1.24 to 1.84) 2.00 (1.69 to 2.35) 1.85 (1.57 to 2.19)
.77 (1.65 to 4.64) 2.57 (1.60 to 4.13) 2.14 (1.30 to 3.51)
.19 (1.40 to 7.27) 2.33 (1.09 to 4.97) 2.59 (1.19 to 5.63)
.01 (1.02 to 3.95) 2.11 (1.16 to 3.82) 1.98 (1.08 to 3.66)
.26 (1.32 to 3.86) 2.11 (1.31 to 3.39) 2.10 (1.29 to 3.42)
.53 (0.78 to 3.03) 2.58 (1.48 to 4.48) 1.85 (1.03 to 3.34)
.24 (0.84 to 1.84) 1.87 (1.35 to 2.60) 1.73 (1.25 to 2.41)
.03 (0.30 to 3.57) 0.90 (0.32 to 2.53) 0.57 (0.16 to 1.97)
.01 (0.73 to 1.40) 1.25 (0.95 to 1.63) 1.38 (1.05 to 1.81)
.95 (0.27 to 3.36) 2.96 (1.16 to 7.56) 2.06 (0.79 to 5.37)
.32 (0.04 to 2.42) 2.40 (0.93 to 6.19) 2.45 (0.95 to 6.31)
ess Index of Australia, Socio-Economic Indexes for Areas and comorbidities.
thic arthritis and undifferentiated spondyloarthritis.
Table 5 Interventions in patients with or without autoimmune rheumatic disease who experienced a first myocardial











Within index MI admission 17,622 (22.6) 190 (13.5) <0.001 0.53 (0.46 to 0.62) <0.001 0.80 (0.68 to 0.94) 0.007
Postdischarge and within 30 days
of index MI episode
1,355 (2.2) 17 (1.4) 0.046 0.62 (0.36 to 0.99) 0.046 0.90 (0.56 to 1.44) 0.652
Between 30 and 90 days of
index MI episode
1,192 (2.0) 14 (1.2) 0.036 0.57 (0.31 to 0.97) 0.036 0.95 (0.55 to 1.66) 0.860
CABG
Within index MI admission 4,592 (5.9) 35 (2.5) <0.001 0.41 (0.29 to 0.57) <0.001 0.50 (0.35 to 0.70) <0.001
Postdischarge and within 30 days
of index MI episode
809 (1.1) 9 (0.7) 0.114 0.59 (0.27 to 1.13) 0.114 0.80 (0.43 to 1.51) 0.498
Between 30 and 90 days of
index MI episode
1,350 (1.9) 9 (0.7) 0.001 0.35 (0.16 to 0.67) 0.001 0.59 (0.30 to 1.15) 0.120
aAIRD, Autoimmune rheumatic disease; CABG, Coronary artery bypass graft; CI, Confidence interval; MI, Myocardial infarction; PTCA, Percutaneous transluminal
coronary angioplasty. bAdjusted for age, sex, Accessibility/Remoteness Index of Australia, Socio-Economic Indexes for Areas and Charlson comorbidities.
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coding more severe cases of AIRD, which would comprom-
ise the generalisability of our findings. Our finding of in-
creased CV mortality across many of the AIRD subgroups
is consistent with the hypothesis of systemic inflammation
contributing to adverse CV outcomes; however, our data
cannot address this specifically. The various disease sub-
groups have different aetiopathogenic mechanisms and
treatment approaches that may increase CV risk via inde-
pendent pathways. For instance, thrombosis may play a
more important role in patients with SLE, whereas pulmon-
ary hypertension and diastolic heart failure may be more
relevant in patients with SSc. We found thrombolysis to be
undercoded, as drug therapies are not routinely captured in
these data, so thrombolysis rates could not be included
in our analyses. We also used data from two different
Australian states, which had different methods of coding
some variables. A number of variables could not be analysed
because of these differences, and our analysis of causes of
death required different methodologies. However, compari-
sons between the two states revealed no significant differ-
ences in the distributions of causes of death. We chose a
5-year look-back period to identify a history of previous MI.
Although this may have misclassified some subsequent MIs
as the first MI, an individual who experienced MI during
the study period and had a history of previous MI more
than 5 years prior would have been likely to receive treat-
ment comparable to that of individuals with a true first
MI [41].
Conclusions
We have demonstrated increased 30-day and 12-month case
fatality rates following an incident MI in patients with a
range of AIRD conditions compared with the general popu-
lation after adjustment for age, sex, SES, regional residenceand significant comorbidities. We also identified lower rates
of PTCA and CABG in the AIRD group within the index
admission. Further studies are required to determine
whether the management of patients with AIRD post-MI
differs from that of non-AIRD patients. In future research,
investigators should examine the use of inflammatory
markers for identifying patients with AIRD who are at high
risk and the influence of anti-inflammatory therapy on CV
risk in patients with AIRD.Additional files
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